TY - JOUR
T1 - Mild cognitive impairment in patients with Parkinson’s disease
T2 - An updated mini-review and future outlook
AU - Yu, Rwei Ling
AU - Wu, Ruey Meei
N1 - Funding Information:
This research was supported by the National Taiwan University 111-UN0007 and Ministry of Science and Technology (MOST), Taipei, Taiwan (MOST 111-2628-B-006-020).
Publisher Copyright:
Copyright © 2022 Yu and Wu.
PY - 2022/9/6
Y1 - 2022/9/6
N2 - Mild cognitive impairment (MCI) is one of the common non-motor symptoms in patients with Parkinson’s disease (PD). MCI is the transition stage between normal aging and full-blown dementia and is also a powerful predictor of dementia. Although the concept of MCI has been used to describe some of the PD symptoms for many years, there is a lack of consistent diagnostic criteria. Moreover, because of the diverse patterns of the cognitive functions, each cognitive impairment will have a different progression. In this review, we overviewed the diagnostic criteria for PD-MCI, primarily focused on the heterogeneity of PD-MCI patients’ cognitive function, including various types of cognitive functions and their progression rates. A review of this topic is expected to be beneficial for clinical diagnosis, early intervention, and treatment. In addition, we also discussed the unmet needs and future vision in this field.
AB - Mild cognitive impairment (MCI) is one of the common non-motor symptoms in patients with Parkinson’s disease (PD). MCI is the transition stage between normal aging and full-blown dementia and is also a powerful predictor of dementia. Although the concept of MCI has been used to describe some of the PD symptoms for many years, there is a lack of consistent diagnostic criteria. Moreover, because of the diverse patterns of the cognitive functions, each cognitive impairment will have a different progression. In this review, we overviewed the diagnostic criteria for PD-MCI, primarily focused on the heterogeneity of PD-MCI patients’ cognitive function, including various types of cognitive functions and their progression rates. A review of this topic is expected to be beneficial for clinical diagnosis, early intervention, and treatment. In addition, we also discussed the unmet needs and future vision in this field.
UR - http://www.scopus.com/inward/record.url?scp=85139234454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139234454&partnerID=8YFLogxK
U2 - 10.3389/fnagi.2022.943438
DO - 10.3389/fnagi.2022.943438
M3 - Review article
AN - SCOPUS:85139234454
VL - 14
JO - Frontiers in Aging Neuroscience
JF - Frontiers in Aging Neuroscience
SN - 1663-4365
M1 - 943438
ER -